MCID: HYP043
MIFTS: 50

Hyperandrogenism

Categories: Endocrine diseases

Aliases & Classifications for Hyperandrogenism

MalaCards integrated aliases for Hyperandrogenism:

Name: Hyperandrogenism 12 72 51 41 14 69
Hyperandrogenization Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11613
MeSH 41 D017588
SNOMED-CT 64 237793004
UMLS 69 C0206081

Summaries for Hyperandrogenism

MalaCards based summary : Hyperandrogenism, also known as hyperandrogenization syndrome, is related to acanthosis nigricans and 3-beta-hydroxysteroid dehydrogenase deficiency. An important gene associated with Hyperandrogenism is WNT4 (Wnt Family Member 4), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Aldosterone synthesis and secretion. The drugs Cyproterone Acetate and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, skin and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 72 Hyperandrogenism, also known as androgen excess, is a medical condition characterized by excessive... more...

Related Diseases for Hyperandrogenism

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 acanthosis nigricans 30.9 INS INSR SHBG
2 3-beta-hydroxysteroid dehydrogenase deficiency 30.1 CYP21A2 HSD3B2
3 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 30.0 CYP21A2 POMC
4 diabetes mellitus 29.9 IGF1 INS INSR SHBG
5 adrenal gland hyperfunction 29.8 CYP21A2 POMC PRL
6 central precocious puberty 29.8 GNRH1 IGF1
7 lipoid congenital adrenal hyperplasia 29.8 CYP17A1 CYP21A2 HSD3B2 POMC
8 hyperthyroidism 29.7 INS PRL SHBG
9 hyperinsulinism 29.7 IGF1 IGFBP1 INS INSR SHBG
10 adrenal adenoma 29.6 CYP17A1 CYP21A2 POMC
11 leydig cell tumor 29.6 CYP17A1 CYP19A1 CYP21A2
12 androgenic alopecia 29.6 CYP19A1 PRL SHBG
13 hyperglycemia 29.6 IGF1 INS INSR
14 conn's syndrome 29.5 CYP17A1 CYP21A2 POMC
15 alopecia, androgenetic, 1 29.5 CYP19A1 CYP21A2 SHBG
16 precocious puberty 29.4 CYP19A1 CYP21A2 GNRH1
17 amenorrhea 29.4 GNRH1 POMC PRL SHBG WNT4
18 adenoma 29.3 IGF1 POMC PRL
19 body mass index quantitative trait locus 11 29.3 CYP21A2 IGF1 IGFBP1 INS INSR POMC
20 transsexualism 29.3 CYP17A1 CYP19A1 CYP21A2
21 hyperprolactinemia 29.2 GNRH1 IGF1 POMC PRL
22 infertility 29.1 CYP19A1 GNRH1 PRL
23 glucose intolerance 29.1 IGF1 IGFBP1 INS INSR SHBG
24 aromatase deficiency 28.9 CYP19A1 GNRH1 INS
25 bipolar disorder 28.9 IGF1 IGFBP1 PRL SHBG
26 insulin-like growth factor i 28.9 IGF1 IGFBP1 INS INSR PRL SHBG
27 anovulation 28.8 CYP19A1 GNRH1 IGF1 INS PRL SHBG
28 acromegaly 28.6 IGF1 IGFBP1 INS POMC PRL
29 polycystic ovary syndrome 28.2 CYP17A1 CYP19A1 CYP21A2 GNRH1 HSD3B2 IGF1
30 endometrial cancer 28.0 CYP19A1 GNRH1 IGF1 IGFBP1 INS SHBG
31 ovarian disease 27.9 CYP19A1 GNRH1 IGF1 IGFBP1 INS PRL
32 mullerian aplasia and hyperandrogenism 12.3
33 hyperandrogenism due to cortisone reductase deficiency 11.9
34 hair-an syndrome 11.8
35 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 11.5
36 mayer-rokitansky-kuster-hauser syndrome 10.8
37 cortisone reductase deficiency 1 10.8
38 diabetes mellitus, insulin-resistant, with acanthosis nigricans 10.8
39 brachyolmia type 4 with mild epiphyseal and metaphyseal changes 10.8
40 cortisone reductase deficiency 2 10.8
41 cortisone reductase deficiency 10.8
42 testotoxicosis 10.8
43 insulin autoimmune syndrome 10.5 INS INSR
44 body mass index quantitative trait locus 9 10.5
45 body mass index quantitative trait locus 8 10.5
46 body mass index quantitative trait locus 7 10.5
47 body mass index quantitative trait locus 12 10.5
48 body mass index quantitative trait locus 14 10.5
49 body mass index quantitative trait locus 18 10.5
50 body mass index quantitative trait locus 4 10.4

Graphical network of the top 20 diseases related to Hyperandrogenism:



Diseases related to Hyperandrogenism

Symptoms & Phenotypes for Hyperandrogenism

GenomeRNAi Phenotypes related to Hyperandrogenism according to GeneCards Suite gene sharing:

25 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.7 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.7 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.7 CYP21A2 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.7 INSR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.7 IGF1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.7 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.7 IGF1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.7 INSR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.7 CYP21A2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.7 SHBG
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.7 IGF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.7 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.7 CYP21A2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.7 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.7 INSR SHBG CYP21A2 IGF1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.7 IGF1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.7 INSR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.7 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.7 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.7 IGF1

MGI Mouse Phenotypes related to Hyperandrogenism:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.02 POMC IGF1 PRL IGFBP1 INS CYP19A1
2 endocrine/exocrine gland MP:0005379 10.01 POMC IGF1 PRL INS CYP19A1 INSR
3 adipose tissue MP:0005375 9.91 POMC IGF1 CYP17A1 INS CYP19A1 INSR
4 integument MP:0010771 9.87 GNRH1 POMC IGF1 PRL INS CYP19A1
5 liver/biliary system MP:0005370 9.8 PRL IGFBP1 INS CYP19A1 INSR GNRH1
6 nervous system MP:0003631 9.76 GNRH1 POMC IGF1 PRL INS CYP19A1
7 renal/urinary system MP:0005367 9.56 IGF1 WNT4 INS CYP17A1 CYP19A1 INSR
8 reproductive system MP:0005389 9.23 IGF1 PRL INS CYP17A1 CYP19A1 INSR

Drugs & Therapeutics for Hyperandrogenism

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
3
Ethinyl Estradiol Approved Phase 4,Phase 2 57-63-6 5991
4
Drospirenone Approved Phase 4 67392-87-4 68873
5
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 4091 14219
6
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0 445154
7
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
8
Simvastatin Approved Phase 4 79902-63-9 54454
9
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
16
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
17
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
19
Enclomiphene Investigational Phase 4,Phase 3,Phase 2 15690-57-0
20 Androgen Antagonists Phase 4,Phase 2
21 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Contraceptive Agents Phase 4,Phase 2
23 Contraceptive Agents, Male Phase 4
24
Cyproterone Phase 4 2098-66-0 5284537
25 Estradiol 17 beta-cypionate Phase 4,Phase 2
26 Estradiol 3-benzoate Phase 4,Phase 2
27 Estradiol valerate Phase 4,Phase 2 979-32-8
28 Estrogens Phase 4,Phase 3,Phase 2
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Polyestradiol phosphate Phase 4,Phase 2
33 Antioxidants Phase 4,Phase 3
34 Contraceptives, Oral Phase 4,Phase 2
35 Contraceptives, Oral, Combined Phase 4,Phase 2
36 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
37 diuretics Phase 4,Phase 3,Phase 2
38 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
39 Drospirenone and ethinyl estradiol combination Phase 4
40 Hemostatics Phase 4
41 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Phase 2
42 Mineralocorticoids Phase 4,Phase 3,Phase 2
43 Natriuretic Agents Phase 4,Phase 3,Phase 2
44 Protective Agents Phase 4,Phase 3
45 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Estrogen Antagonists Phase 4,Phase 3,Phase 2
47 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Early Phase 1
50 Incretins Phase 4

Interventional clinical trials:

(show top 50) (show all 117)

# Name Status NCT ID Phase Drugs
1 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
2 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
4 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
5 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
6 Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos. Completed NCT01896492 Phase 4 NAC
7 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
8 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
9 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
10 Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
11 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Recruiting NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
12 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
13 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Recruiting NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
14 Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism Recruiting NCT01721915 Phase 4 Vitamin D supplementation;Placebo
15 Research of Exenatide for Overweight/Obese PCOS Patients With IGR Recruiting NCT03352869 Phase 4 Exenatide;Metformin
16 Research of Intensive Metabolic Intervention Before Pregnancy in PCOS Not yet recruiting NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
17 Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Unknown status NCT01782911 Phase 3
18 Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study Unknown status NCT02133755 Phase 3 Bromocriptine
19 Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
20 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
21 Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Completed NCT01482286 Phase 3 Metformin
22 The Adrenal Contribution to Androgen Production in Girls During Puberty Completed NCT01062568 Phase 3 Adrenocorticotropin;Dexamethasone
23 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3 recombinant human chorionic gonadotropin
24 Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Completed NCT01961336 Phase 3 Testosterone
25 Obesity in Children and Adolescents: Associated Risks and Early Intervention Completed NCT01677923 Phase 3 Metformin
26 Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman. Recruiting NCT03334682 Phase 3 spironolactone;Doxycycline
27 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
28 Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism Completed NCT00004763 Phase 2 leuprolide;Ethinyl estradiol/norethindrone
29 Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women Completed NCT00704912 Phase 2 Orlistat/Meal Replacement/Lifestyle Modification;Loestrin 1/20;Combination of treatments
30 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
31 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2 Hydrocortisone (Solucortef)
32 Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients Completed NCT02562664 Phase 2 CC;Placebo tablets;Metformin
33 Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
34 Acupuncture or Metformin for Insulin Resistance in Women With PCOS Recruiting NCT02647827 Phase 2 Metformin
35 Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome Recruiting NCT02644304 Phase 2 Clomiphene citrate;Cabergoline
36 Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome Recruiting NCT03152591 Phase 2 LIK066;Placebo
37 Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant Enrolling by invitation NCT02523898 Phase 2 metformine;placebo;clomiphene citrate
38 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Not yet recruiting NCT03229408 Phase 2 Salsalate
39 Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome Completed NCT01457209 Phase 1
40 Time Course of Waking Versus Sleep-associated Luteinizing Hormone (LH) Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia Recruiting NCT00929006 Phase 1 Micronized progesterone suspension;Placebo
41 Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone Recruiting NCT01428089 Phase 1 Progesterone;Placebo
42 Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006) Active, not recruiting NCT01602679 Phase 1 oral micronized progesterone suspension;Placebo
43 Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Terminated NCT01489319 Phase 1 Salsalate;Salsalate
44 Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01569425
45 Meal Timing on Glucose and Hyperandrogenism in PCOS Women Unknown status NCT01711476
46 Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT02402413
47 Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome Unknown status NCT00784615
48 The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome Unknown status NCT02126592
49 Metabolic Disorders in Polycystic Ovarian Syndrome Unknown status NCT00172523
50 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome Unknown status NCT00665171

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Genetic Tests for Hyperandrogenism

Anatomical Context for Hyperandrogenism

MalaCards organs/tissues related to Hyperandrogenism:

38
Ovary, Skin, Testes, Liver, Bone, Hypothalamus, Pituitary

Publications for Hyperandrogenism

Articles related to Hyperandrogenism:

(show top 50) (show all 658)
# Title Authors Year
1
Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. ( 29273198 )
2018
2
Progesterone Suppression of Luteinizing Hormone Pulse Frequency in Adolescent Girls With Hyperandrogenism: Effects of Metformin. ( 29095983 )
2018
3
Improvement of hyperandrogenism, oligo-ovulation, and ovarian morphology in a patient with polycystic ovary syndrome: possible role of ovarian wedge resection. ( 29298536 )
2018
4
Infertile polycystic ovary syndrome patients undergoing in vitro fertilization with the gonadotropin-releasing hormone-antagonist protocol: role of hyperandrogenism. ( 29376451 )
2018
5
Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. ( 29068242 )
2018
6
Hyperandrogenism controversy in elite women's sport: an examination and critique of recent evidence. ( 29351951 )
2018
7
Gut Microbial Diversity in Women with Polycystic Ovary Syndrome Correlates with Hyperandrogenism. ( 29370410 )
2018
8
Value of selective venous catheterization in the diagnosis of hyperandrogenism. ( 29100622 )
2017
9
Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. ( 28370150 )
2017
10
Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype? ( 28649885 )
2017
11
Prevalence of Prediabetes Risk in Offspring Born to Mothers with Hyperandrogenism. ( 28111236 )
2017
12
Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. ( 28575537 )
2017
13
Hyperandrogenism in a postmenopausal woman: a rare case of ectopic adrenal cortical gland. ( 28102088 )
2017
14
The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. ( 28620353 )
2017
15
The prevalence of non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Russian women with hyperandrogenism. ( 28669219 )
2017
16
Effect of TNF-I+ on Molecules Related to the Insulin Action in Endometrial Cells Exposed to Hyperandrogenic and Hyperinsulinic Conditions Characteristics of Polycystic Ovary Syndrome. ( 28946816 )
2017
17
Very low dose of flutamide in the treatment of hyperandrogenism. ( 29108453 )
2017
18
Identification of microRNAs and genes associated with hyperandrogenism in the follicular fluid of women with polycystic ovary syndrome. ( 29193229 )
2017
19
Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS. ( 28912337 )
2017
20
An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients. ( 28125989 )
2017
21
The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse. ( 28961951 )
2017
22
Animal models of hyperandrogenism and ovarian morphology changes as features of polycystic ovary syndrome: a systematic review. ( 28183310 )
2017
23
Hyperandrogenism in adolescent girls: relationship with the somatotrophic axis. ( 28593921 )
2017
24
Transient hyperandrogenism in 2 preterm twins with exposure to antiretrovirals. ( 28864089 )
2017
25
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. ( 29161258 )
2017
26
Hyperandrogenism stimulates inflammation and promote apoptosis of cumulus cells. ( 29096744 )
2017
27
Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS. ( 28724177 )
2017
28
Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China. ( 28413474 )
2017
29
Correction to: Fulghesu etA al., Very low dose of flutamide in the treatment of hyperandrogenism. ( 29171313 )
2017
30
Expression of AKT1 along with AKT2 in granulosa-lutein cells of hyperandrogenic PCOS patients. ( 28271235 )
2017
31
Treatment of hyperandrogenism in women with ethinylestradiol and cyproteroneacetate. ( 28540758 )
2017
32
A peel-off facial mask comprising myoinositol and trehalose-loaded liposomes improves adult female acne by reducing local hyperandrogenism and activating autophagy. ( 28342238 )
2017
33
The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model. ( 28572510 )
2017
34
Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. ( 28089571 )
2017
35
Postmenopausal hyperandrogenism of ovarian origin: A clinicopathologic study of five cases. ( 28096644 )
2016
36
Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective. ( 26964728 )
2016
37
Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage In Normal Weight Polycystic Ovary Syndrome Women. ( 27571186 )
2016
38
Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome. ( 27336356 )
2016
39
Metformin for women with hyperandrogenic anovulation. ( 26906093 )
2016
40
The Relationship Between Hearing Thresholds and Hyperandrogenism in Polycystic Ovary Syndrome. ( 27846196 )
2016
41
Postmenopausal hyperandrogenism: the under-recognized value of inhibins. ( 27278937 )
2016
42
Synchronous Ileal Neuroendocrine Tumor and Ovarian Steroid Cell Tumor Present in a Female With Hyperandrogenism. ( 27167674 )
2016
43
Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism. ( 27060006 )
2016
44
Ethics of Regulating Competition for Women with Hyperandrogenism. ( 26832978 )
2016
45
Gestational Hyperandrogenism in Developmental Programming. ( 27967205 )
2016
46
The 2015 Pediatric Endocrine Society Ethics Symposium: Controversies Regarding 'Gender Verification' of Elite Female Athletes - Sex Testing to Hyperandrogenism. ( 26918844 )
2016
47
Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism. ( 27179108 )
2016
48
Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. ( 26951881 )
2016
49
A Case of Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans Syndrome; Increase in Proliferating Cell Nuclear Antigen and Decrease in Loricrin in Acanthosis Nigricans. ( 27746646 )
2016
50
Reply: Metformin for women with hyperandrogenic anovulation. ( 26906091 )
2016

Variations for Hyperandrogenism

Expression for Hyperandrogenism

Search GEO for disease gene expression data for Hyperandrogenism.

Pathways for Hyperandrogenism

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 IGF1 INS INSR PRL WNT4
2
Show member pathways
12.5 CYP17A1 CYP21A2 HSD3B2 INS POMC
3
Show member pathways
12.22 IGF1 INS INSR WNT4
4 12.14 CYP17A1 CYP19A1 IGFBP1 INS INSR
5
Show member pathways
12.03 IGF1 INS POMC
6
Show member pathways
11.93 IGF1 INS INSR
7
Show member pathways
11.86 IGF1 INS INSR
8 11.7 IGF1 INS INSR
9 11.65 IGF1 INS WNT4
10 11.62 CYP21A2 HSD3B2 POMC
11
Show member pathways
11.31 CYP17A1 CYP19A1 HSD3B2
12
Show member pathways
11.3 CYP17A1 CYP19A1 CYP21A2 HSD3B2 POMC
13
Show member pathways
11.27 CYP17A1 CYP19A1 CYP21A2 HSD3B2
14 11.24 INS INSR PRL
15 11.07 IGF1 INS INSR
16 11.05 INS INSR
17
Show member pathways
10.91 CYP17A1 CYP21A2
18 10.88 IGF1 IGFBP1
19 10.8 CYP17A1 CYP19A1 HSD3B2 IGF1 INS INSR
20 10.79 GNRH1 SHBG

GO Terms for Hyperandrogenism

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 GNRH1 IGF1 IGFBP1 INS POMC PRL
2 endosome lumen GO:0031904 8.96 INS PRL

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 IGF1 IGFBP1 INS PRL
2 regulation of receptor activity GO:0010469 9.8 GNRH1 IGF1 INS POMC PRL WNT4
3 glucose homeostasis GO:0042593 9.76 INS INSR POMC
4 positive regulation of MAPK cascade GO:0043410 9.74 IGF1 INS INSR
5 insulin receptor signaling pathway GO:0008286 9.73 IGFBP1 INS INSR
6 positive regulation of DNA replication GO:0045740 9.67 IGF1 INS INSR
7 activation of protein kinase B activity GO:0032148 9.65 IGF1 INS INSR
8 positive regulation of glucose import GO:0046326 9.63 IGF1 INS INSR
9 regulation of multicellular organism growth GO:0040014 9.61 IGF1 PRL
10 female gonad development GO:0008585 9.61 CYP19A1 WNT4
11 positive regulation of mitotic nuclear division GO:0045840 9.61 IGF1 INS INSR
12 sex differentiation GO:0007548 9.6 CYP17A1 WNT4
13 adrenal gland development GO:0030325 9.59 INSR WNT4
14 male sex determination GO:0030238 9.58 GNRH1 INSR
15 sterol metabolic process GO:0016125 9.58 CYP17A1 CYP19A1 CYP21A2
16 positive regulation of respiratory burst GO:0060267 9.55 INS INSR
17 neuron projection maintenance GO:1990535 9.54 INS INSR
18 positive regulation of glycolytic process GO:0045821 9.54 IGF1 INS INSR
19 mineralocorticoid biosynthetic process GO:0006705 9.51 CYP21A2 HSD3B2
20 steroid biosynthetic process GO:0006694 9.46 CYP17A1 CYP19A1 CYP21A2 HSD3B2
21 positive regulation of glycogen biosynthetic process GO:0045725 9.43 IGF1 INS INSR
22 androgen biosynthetic process GO:0006702 9.13 CYP17A1 HSD3B2 WNT4
23 glucocorticoid biosynthetic process GO:0006704 8.8 CYP17A1 CYP21A2 HSD3B2

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.58 CYP17A1 CYP19A1 CYP21A2
2 heme binding GO:0020037 9.54 CYP17A1 CYP19A1 CYP21A2
3 insulin receptor binding GO:0005158 9.48 IGF1 INS
4 steroid binding GO:0005496 9.46 CYP21A2 SHBG
5 steroid hydroxylase activity GO:0008395 9.43 CYP19A1 CYP21A2
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.43 CYP17A1 CYP19A1 CYP21A2
7 insulin-like growth factor I binding GO:0031994 9.32 IGFBP1 INSR
8 insulin-like growth factor II binding GO:0031995 9.16 IGFBP1 INSR
9 insulin-like growth factor receptor binding GO:0005159 9.13 IGF1 INS INSR
10 hormone activity GO:0005179 9.02 GNRH1 IGF1 INS POMC PRL

Sources for Hyperandrogenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....